MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-17-2025
Zynex Operating Income 2011-2026 | ZYXI
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Zynex
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.99 M | 10.8 M | 22.9 M | 22.4 M | 10.2 M | 11.1 M | 10.4 M | 8.94 M | 640 K | -2.48 M | -5.7 M | -7.6 M | 2.74 M | 3.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 22.9 M | -7.6 M | 6.67 M |
Quarterly Operating Income Zynex
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -44 M | -10.3 M | -13.1 M | - | 3.8 M | 2.23 M | 525 K | - | 5.48 M | 2.71 M | 284 K | - | 6.56 M | 4.36 M | 1.91 M | 11.6 M | 8.05 M | 3.81 M | -1.08 M | 2.3 M | 1.41 M | 4.08 M | 2.46 M | 3.73 M | 2.5 M | 2.58 M | 2.26 M | 2.88 M | 2.82 M | 2.72 M | 1.96 M | 3.59 M | 2.94 M | 1.93 M | 483 K | 518 K | 622 K | -150 K | -350 K | - | -226 K | -363 K | -772 K | - | 412 K | -5.42 M | -1.29 M | - | -1.07 M | -2.56 M | -362 K | - | 712 K | 932 K | 486 K | - | 1.1 M | 899 K | -139 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 11.6 M | -44 M | 323 K |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K |  USA |
 |
Axonics Modulation Technologies
AXNX
|
-26.1 M | - | - | $ 3.31 B | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
ClearPoint Neuro
CLPT
|
-24.2 M | $ 11.16 | -0.09 % | $ 316 M | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Alphatec Holdings
ATEC
|
-82.1 M | $ 8.27 | 0.55 % | $ 1.24 B | USA |
 |
Aziyo Biologics
AZYO
|
-26.9 M | - | 1.37 % | $ 20.5 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 4.33 | 0.23 % | $ 162 M |  France |
 |
BioSig Technologies
BSGM
|
-71.1 M | - | 37.08 % | $ 85.7 M | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
LENSAR
LNSR
|
-24.6 M | $ 5.86 | 1.03 % | $ 70.1 M | USA |
 |
Helius Medical Technologies
HSDT
|
-244 M | $ 2.31 | 6.94 % | $ 50.9 M | USA |
 |
Cytosorbents Corporation
CTSO
|
-14.7 M | $ 0.47 | -0.53 % | $ 29.2 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 18.4 | 0.93 % | $ 432 M | USA |
 |
LivaNova PLC
LIVN
|
199 M | $ 73.67 | 1.03 % | $ 4.02 B |  Britain |
 |
MiMedx Group
MDXG
|
63.9 M | $ 3.77 | 3.43 % | $ 557 M | USA |
 |
Delcath Systems
DCTH
|
660 K | $ 11.2 | 3.23 % | $ 401 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
IRIDEX Corporation
IRIX
|
-2.57 M | $ 1.0 | -4.29 % | $ 16.9 M | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
Pulmonx Corporation
LUNG
|
-53.7 M | $ 1.54 | 14.55 % | $ 62.7 M | USA |
 |
Electromed
ELMD
|
9.66 M | $ 37.58 | -2.06 % | $ 318 M | USA |
 |
Myomo
MYO
|
-14.4 M | $ 0.9 | 3.7 % | $ 37.7 M | USA |
 |
Butterfly Network
BFLY
|
-86.4 M | $ 4.42 | 7.8 % | $ 1.09 B | USA |
 |
Second Sight Medical Products
EYES
|
-27.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
Orthofix Medical
OFIX
|
-81.4 M | $ 12.16 | 0.58 % | $ 482 M |  Curacao |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
Sintx Technologies
SINT
|
-10.7 M | $ 2.19 | -0.45 % | $ 6.07 M | USA |
 |
Profound Medical Corp.
PROF
|
-41.3 M | $ 6.95 | 3.19 % | $ 210 M | Canada |
 |
Globus Medical
GMED
|
480 M | $ 83.98 | 5.06 % | $ 11.4 B | USA |
 |
Insulet Corporation
PODD
|
474 M | $ 157.2 | 1.68 % | $ 11.1 B | USA |
 |
CONMED Corporation
CNMD
|
103 M | $ 36.7 | 1.44 % | $ 1.14 B | USA |
 |
Inspire Medical Systems
INSP
|
51 M | $ 44.19 | 3.87 % | $ 1.3 B | USA |
 |
TransMedics Group
TMDX
|
109 M | $ 68.79 | 4.01 % | $ 2.34 B | USA |
 |
Integer Holdings Corporation
ITGR
|
221 M | $ 91.17 | 0.81 % | $ 3.17 B | USA |
 |
Invacare Corporation
IVC
|
-80.5 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
1.26 B | $ 82.96 | 0.97 % | $ 48.5 B | USA |